[{"id":"da-biogen","kind":"company","name":"Biogen","aka":[],"tldr":"Biogen partnered on lecanemab and previously marketed aducanumab.","summary":"Aducanumab’s withdrawn indication is recorded on the product page so history is not mistaken for a current option.","asOf":"2026-09-21","links":[{"label":"Biogen","url":"https://www.biogen.com/"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-lecanemab","da-aducanumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"pharma","website":"https://www.biogen.com/","investors":[],"funding":[]},{"id":"da-eisai","kind":"company","name":"Eisai","aka":[],"tldr":"Eisai is a medicines company that co-developed lecanemab.","summary":"Listed as the lecanemab sponsor partner on this atlas. Company pages here are map nodes, not investment advice.","asOf":"2026-09-21","links":[{"label":"Eisai","url":"https://www.eisai.com/"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-lecanemab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-clarity-ad"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.eisai.com/","investors":[],"funding":[]},{"id":"da-lilly","kind":"company","name":"Eli Lilly","aka":[],"tldr":"Lilly developed donanemab and is running further amyloid-antibody studies.","summary":"Donanemab and remternetug sit on this company’s node so pipeline and approved products stay distinct.","asOf":"2026-09-21","links":[{"label":"Lilly","url":"https://www.lilly.com/"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-donanemab","da-remternetug"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-trailblazer-alz2","da-trial-expedition3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Indianapolis","country":"US","companyType":"pharma","website":"https://www.lilly.com/","investors":[],"funding":[]}]